Acute HCV in HIV-positive individuals - A review

Current Pharmaceutical Design

Volumn 14, Issue 17, 2008, Pages 1690-1697

  Danta, M ^a   Dusheiko, G M ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Acute; Epidemiology; HCV; HIV; Interferon; Natural history; Transmission

Indexed keywords

ALPHA INTERFERON; DIDANOSINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ZIDOVUDINE;

ACUTE HEPATITIS; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; HEALTH PROMOTION; HEPATITIS C; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RESISTANCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE FUNCTION; MIXED INFECTION; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; TREATMENT DURATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ACUTE DISEASE; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HIV INFECTIONS; HUMANS; T-LYMPHOCYTES;

EID: 47349112672     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784746761     Document Type: Review

References (82)

1. World Health Organisation regional office for Europe, [http://www.euro.who.int/HEN/Syntheses/hepatitisC/20050411_7]. 26 April 2005 [cited March 2006].
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-9.
3. Palella F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
4. Bica I, McGovern B, Dhar R, Stone D, McGowan Y, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-7.
5. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: A cohort study. J Acquir Immune Defic Syndr 2000; 24: 211-7.
6. Browne R, Asboe D, Gilleece Y, Atkins M, Mandalia S, Gazzard B, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect 2004; 80: 326-7.
7. Gambotti L, Batisse D, Colin-de-Verdiere N, Delaroque-Astagneau E, Desenclos J, Dominguez S, et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill 2005; 10: 115-7.
8. Gotz H, van Doomum G, Niesters H, den Hollander J, Thio H, de Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications. AIDS 2005; 19: 969-74.
9. Luetkemeyer A, Hare C, Stansell J, Tien P, Charlesbois E, Lum P, et al. Clinical Presentation and Course of Acute Hepatitis C Infection in HIV-Infected Patients. J Acquir Immune Defic Syndr 2006; 41: 31-6.
10. Bateman K, Factor S, Gutierrez J, Fierer D, Uriel A, Carriero D. Evidence for sexual transmission of hepatitis C virus infection in men who have sex with men [MSM] in New York City. In 14th International Symposium on hepatitis C virus and related viruses: Glasgow 2007.
11. Matthews G, Hellard M, Kaldor J, Lloyd A, Dore G. Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al. AIDS 2007; 21: 2112-3.
12. Hoofnagle J. Hepatitis C: The clinical spectrum of disease. Hepatology 1997; 26: 15S-20S.
13. Gerlach J, Diepolder H, Zachoval R, Gruener N, Jung M, Ulsenheimer A, et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-4
14. CDC. Updated U.S. Public health service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001; 50: 1-52.
15. Verucchi G, Calza, L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: Epidemiology, natural history, therapeutic options and clinical management. Infection 2004; 32: 33-46.
16. Gibb D, Goodall R, Dunn D, Healy M, Neave P, Cafferkey M, et al. Mother-to-child transmission of hepatitis C virus: Evidence for preventable peripartum transmission. Lancet 2000; 356: 904-7.
17. Alter M. Prevention of spread of hepatitis C. Hepatology 2002; 36: S93-8.
18. Amin J, Kaye M, Skidmore S, Pillay D, Cooper D, Dore G. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004; 5: 174-9.
19. Mohsen A, Murad S, Easterbrook P. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in South London. HIV Med 2005; 6: 206-15.
20. Giraudon I, Ruf M, Maguire H, Charlett A, Ncube F, Turner J, et al. Increase in newly acquired hepatitis C in HIV positive men who have sex with men across London and Brighton, 2002-2006. Is this an outbreak? Sex Transm Infect 2008; 84(2): 111-5.
21. Fox J, Thompson E, Nastouli E. Increasing incidence of acute hepatitis C in a cohort of individuals diagnosed with primary HIV. In 4th International AIDS Society Conference on HIV pathogenesis, treatment and prevention: Sydney 2007.
22. Danta M, Brown D, Bhagani S, Pybus O, Sabin C, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 983-91.
23. van de Laar T, van der Bij A, Prins M, Bruisten S, Brinkman K, Ruys T, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196: 230-8.
24. Danta M, van de Laar T, Brown D, Pybus O, Bhagani S, Vogel M, et al. Evidence of international transmission of HCV in pan-European study of HIV-positive men who have sex with men. In American Association for the study of liver diseases: Boston, USA 2007.
25. Briat A, Dulioust E, Galimand J, Fontaine H, Chaix M, Letur-Konirsch H, et a. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. AIDS 2005; 19: 1827-35.
26. Schmidt A, Vogel M, Rockstroh J. A preliminary evaluation of a case control study. In 4th International AIDS Society Conference on HIR pathogenesis, treatment and prevention. Sydney, Australia 2007.
27. CDC. Recommendations for prevention and control of heptitis C virus [HCV] infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47: 1-39.
28. Macdonald N, Dougan S, McGarrigle, C, Baster K, Rice B, Evans B, et al. A. Recent trends in diagnoses of HIV and other sexually transmitted infections in England and Wales among men who have sex with men. Sex Transm Infect 2004; 80: 492-7.
29. Simms I, Fenton K, Ashton M, Turner K. Crawley-Boevey E, Gorton R, et al. The re-emergence of syphilis in the United Kingdom: The new epidemic phases. Sex Transm. Dis 2005; 32: 220-6.
30. Dodds J, Nardone A, Mercey D, Johnson A. Increase in high risk exual behaviour among homosexual men, London 1996-8: Cross sectional, questionnaire study. BMJ 2000; 320: 1510-1.
31. Nardone A, Mercey D, Johnson A. Surveillance of sexual behaviour among homosexual men in a central London health authority. Genitourin Med 1997; 73: 198-202.
32. Dodds J, Mercey D, Parry J, Johnson A. Increasing risk behaviour and high levels of undiagnosed HIV infection in a community sample of homosexual men. Sex Transm Infect 2004; 80: 236-40.
33. McConell J. Sorting out serosorting with sexual network methods. In 10th Conference on retroviruses and opportunistic infections: Boston, MA 2003.
34. Halkitis P, Green K, Remien R, Stirratt M, Hoff C, Wolitski R, et al. Seroconcordant sexual partnerings of HIV-seropositive men who have sex with men. AIDS 2005; 19: S77-86.
35. Halkitis P, Wilton L, Wolitski R, Parsons J, Hoff C, Bimbi D. Barebacking identity among HIV-positive gay and bisexual men: demographic, psychological, and behavioral correlates. AIDS 2005; 19: S27-35.
36. McFarlane M, Bull S, Rietmeijer C. The Internet as a newly emerging risk environment for sexually transmitted diseases. JAMA 2000; 284: 443-6.
37. Wong W, Chaw J, Kent C, Klausner J. Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003. Sex Transm Dis 2005; 32: 458-63.
38. Hospers H, Kok G, Harterink P, de Zwart O. A new meeting place: Chatting on the Internet, e-dating and sexual risk behaviour among Dutch men who have sex with men. AIDS 2005; 19: 1097-101.
39. Bolding G, Davis M, Hart G, Sherr L, Elford J. Gay men who look for sex on the Internet: Is there more HIV/STI risk with online partners? AIDS 2005; 19: 961-8.
40. Fenton K, Mercer C, Johnson A, Byron C, McManus S, Erens B, et al. Reported sexually transmitted disease clinic attendance and sexually transmitted infections in Britain: Prevalence, risk factors, and proportionate population burden. J Infect Dis 2005; 191(Suppl 1): S127-38.
41. Stamm W, Handsfield H, Rompalo A, Ashley R, Roberts P, Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988; 260:1429-33.
42. Mattapallil J, Douek D, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005; 434: 1093-7.
43. Diepolder H, Zachoval R, Hoffmann R, Wierenga E, Santantonio T, Jung M, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-7.
44. Gerlach J, Diepolder H, Jung M, Gruener N, Schraut W, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4[+] T-cell response in acute hepatitis C. Gastroenterology 1999; 117:933-41.
45. Thimme R, Oldach D, Chang K, Steiger C, Ray S, Chisari F. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-406.
46. Thimme R, Bukh J, Spangenberg H, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99: 15661-8.
47. Lamonaca V, Missale G, Urbani S, Pilli M, Boni C, Mori C, et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4[+] T cells: Implications for vaccine development. Hepatology 1999; 30: 1088-98.
48. Diepolder H, Gerlach J, Zachoval R, Hoffmann R, Jung M, Wierenga, E, et al. Immunodominant CD4+ T-cell epitope within non-structural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71: 6011-9.
49. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immime responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-82.
50. Shoukry N, Grakoui A, Houghton M, Chien D, Ghrayeb J, Reimann K, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;,197: 1645-55.
51. Gruner N, Gerlach T, Jung M, Diepolder H, Schirren C, Schraut W, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181: 1528-36.
52. Lechner F, Wong D, Dunbar P, Chapman R, Chung R, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-512.
53. Harcourt G, Gomperts E, Donfield S, Klenerman P. Profound loss of HCV-specific interferon-gamma secreting CD4+ T cells in HIV/HCV co-infected patients. Gut 2006; 55(10): 1484-7.
54. Klenerman P, Kim A. HCV-HIV coinfection: Simple messages from a complex disease. PLoS Med 2007; 4: E240.
55. Gilleece Y, Browne R, Asboe D, Atkins M, Mandalia S, Bower M, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005; 40:41-6.
56. Danta M, Semmo N, Fabris P, Brown D, Pybus O, Sabin C, et al. Impact of HIV on host-virus interactions in early HCV infection. J Infect Dis 2008; April 17 Epub ahead of print.
57. Micallef J, Kaldor J, Dore G. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
58. Neumann-Haefelin C, Blum H, Chisad F, Thimme R. T cell response in hepatitis C virus infection. J Clin Virol 2005; 32: 75-85.
59. Bukh J, Miller R, Purcell R. Genetic heterogeneity hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.
60. Mao Q, Ray S, Laeyendecker O, Ticehurst J, Strathdee S, Vlahov D, et al. Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol 2001; 75: 3259-67.
61. Sherman K, Andreatta C, O'Brien J, Gutierrez A, Harris R. Hepatitis C in human immunodeficiency virus-coinfected patients: Increased variability in the hypervariable envelope coding domain. Hepatology 1996; 23:688-94.
62. Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H, Hayakawa T. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. J Hepatol 1997; 26: 975-82.
63. Roque-Afonso A, Robain M, Simoneau D. Rodriguez-Mathieu P, Gigou M, Meyer L, et al. J Infect Dis 2002; 185: 728-33.
64. Neau D, Jouvencel A, Legrand E, Trimoulet P, Galperine T, Chitty I, et al. Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients. J Med Virol 2003; 71: 41-8.
65. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-7.
66. Wiegand J, Jackel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40: 98-107.
67. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
68. Kamal S, Ismail A, Graham C, He Q, Rasenack J, Peters T, et al. Pegylated interferon alpha therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics. J Hepatol 2004; 39: 1721-31.
69. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42: 329-33.
70. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimuru Y, Hayashi J, et al. Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial. Hepatology 2004; 39: 1213-9.
71. Torriani F, Rodriguez-Torres M, Rockstoh J, Lissen H, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
72. Chung R, Andersen J, Volberding P, Robbins G, Liu T, Sherman K, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
73. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004; 292: 2839-48.
74. Serpaggi J, Chaix M, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in MV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20: 233-240.
75. Danta M, Turner J, Johnstone R, Lascar R, Johnson M, Dusheiko G, et al. Early ribavirin improves sustained virological responses in acute HCV infection in HIV-positive individuals. Hepatology 2005; 42: A920.
76. Vogel M, Bieniek B, Jessen H, Schewe C, Hoffmann C, Baumgarten A, et al. Treatment of acute hepatitis C infection in HIV-infected patients: A retrospective analysis of eleven cases. J Viral Hepat 2005; 12: 207-11.
77. Dore G, Torriani F, Rodriguez-Torres M, Brau N, Sulkowski M, Lamoglia. R, et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS 2007; 21: 1555-9.
78. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-1.
79. Nelson M, Matthews G, Brook M. BHIVA guidelines on HIV and chronic hepatitis: Coinfection with HIV and hepatitis C virus infection (2005). J HIV Med 2005; 6(Suppl 2): 96-106.
80. Pepe M, Altamura M, Spinelli R, Calvello R, Saccia M, Cavallo P, et al. Toll-like receptor-positive cells and recognition of pathogens: how human myeloid dendritic cells respond to in vitro infection with Leishmani infantum. Curr Pharm Des 2006; 12(32):4255-62.
81. Pepe M, Jirillo E, Covelli V. In vitro infection of human monocyte-derived dendritic cells with Candida albicans: Receptorial involvement and therapeutic implications. Curr Pharm Des 2006; 12(32): 4263-9.
82. Tsai CH, Lee PY, Stollar V, Li ML. Antiviral therapy targeting viral polymerase. Curr Pharm Des 2006; 12(1): 1339-55.